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Malignant glioma including glioblastoma (GBM) is the most common group of primary
brain tumors. Despite standard optimized treatment consisting of extensive resection
followed by radiotherapy/concomitant and adjuvant therapy, GBM remains one of the
most aggressive human cancers. GBM is a typical example of intra-heterogeneity
modeled by different micro-environmental situations, one of the main causes of
resistance to conventional treatments. The resistance to treatment is associated with
angiogenesis, hypoxic and necrotic tumor areas while heterogeneity would accumulate
during glioma cell invasion, supporting recurrence. These complex mechanisms require
a focus on potential new molecular actors to consider new treatment options for
gliomas. Among emerging and underexplored targets, transient receptor potential (TRP)
channels belonging to a superfamily of non-selective cation channels which play critical
roles in the responses to a number of external stimuli from the external environment
were found to be related to cancer development, including glioma. Here, we discuss the
potential as biological markers of diagnosis and prognosis of TRPC6, TRPM8, TRPV4,
or TRPV1/V2 being associated with glioma patient overall survival. TRPs-inducing
common or distinct mechanisms associated with their Ca2+-channel permeability
and/or kinase function were detailed as involving miRNA or secondary effector signaling
cascades in turn controlling proliferation, cell cycle, apoptotic pathways, DNA repair,
resistance to treatment as well as migration/invasion. These recent observations of the
key role played by TRPs such as TRPC6 in GBM growth and invasiveness, TRPV2
in proliferation and glioma-stem cell differentiation and TRPM2 as channel carriers of
cytotoxic chemotherapy within glioma cells, should offer new directions for innovation
in treatment strategies of high-grade glioma as GBM to overcome high resistance
and recurrence.
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INTRODUCTION
Malignant gliomas are the most prevalent group of primary brain tumors in adults, with an
incidence of 8.9 cases per 100,000 persons/year in the US (Ostrom et al., 2015, 2017). Glioblastoma
(GBM) remains one of the most aggressive human cancers. Glial tumors or glioma represent a
wide spectrum of malignancies including grades II and III oligodendroglioma, grades II and III
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astrocytoma and glioblastoma from initial classification based
on anatomocytopathological criteria related to the morphotypic
characteristics and numerous cytonuclear atypologies,
accompanied by anaplasia for high-grade glioma (GBM, grade
IV) (Louis et al., 2007; Miller and Perry, 2007). The diagnosis of
GBM was based on the presence of vascular micro-proliferations
signs of intense vascularization, associated with zones of necrosis
delimited by a hypoxic pseudopalissadic cellular zone, evidencing
important intra-tumoral heterogeneity (Karsy et al., 2012;
Alifieris and Trafalis, 2015). Now, brain tumors and glioma are
classified according to the histomolecular classification recently
published by the World Health Organization (WHO) (Louis
et al., 2016), which represents a major clinical improvement for
both diagnosis and treatments, as well as patient prognosis. The
aim was to implement the histopathological classification with
the following molecular signatures: first including the mutation
in the isocitrate dehydrogenase1/2 (IDH1/2mut) and/or the co-
deletion 1p/19q associated with oligodendroglioma or mutation
of TP53; second the l′α-thalassemia mental retardation syndrome
X-linked (ATX) or amplification of the epidermal growth factor
receptor (EGFR) were associated with GBM IDHwt; finally
the hypermethylation of the O6-methyl guanine-DNA methyl
transferase (MGMT) promoter constitutes an important
parameter of the GBM aggressiveness (Louis et al., 2016).
Despite these molecular attempts to stratify glioma
patients with the objective to allow personalization of the
treatments, the median survival of GBM patients currently
ranges from 15 to 17 months, despite a safe maximal surgical
resection, radiation/concomitant and adjuvant alkylating-based
chemotherapy by temozolomide (TMZ) (Stupp et al., 2005, 2009;
Wen and Brandes, 2009). However, more than 95% of GBM recur
in the margin of the resection cavity, an area in which glioma
tumor cells acting as a tumor reservoir are found (Giese et al.,
2003). This invasiveness associated with X-ray and/or intrinsic
or acquired chemoresistance of the glioma cells and the presence
of an intrinsic or acquired blood-brain barrier (BBB), limit
the effectiveness and/or the delivery of anti-neoplastic agents
and justify the development of new strategies. In agreement,
over the last decade, despite very important advances in the
field of targeted therapy, none of them, e.g., drug/antibody or
combination of small molecule inhibitors, has been shown to be
more effective than TMZ or capable of increasing the efficacy
of standard therapy in patients with primary or recurrent GBM
(Stepanenko and Chekhonin, 2018), and no curative treatment
is currently identified in GBM. This failure may be explained
at least in part by the intratumoral heterogeneity which is a
conserved consequence of the GBM micro-environment (Prabhu
et al., 2017), referring to the physico-chemical characteristics
and matrices interacting with the tumor. Indeed, the GBM
heterogeneity is tightly related to angiogenic and hypoxic
features as well as invasive processes, thus future strategies
should consider targeting mechanisms associated with resistance
and invasion. In particular, Watkins et al. (2014) showed
that GBM cells can thus control the regulation of vascular
tone, via the release of K+ through K+ channels activated in
response to Ca2+, leading to an adaptation of cell volume to
facilitate their invasion.
Transient receptor potential (TRP) channels are a superfamily
of cationic tetrameric channels, mostly permeable to Ca2+,
involved in various physiological functions, and for the
most part sustain calcium homeostasis and calcium signaling.
Calcium-dependent mechanisms determine several aspects of
brain tumor cell homeostasis including survival, proliferation,
invasion or treatment resistance, making TRP channels putative
potent modulators of tumorigenesis and glioma progression.
Approximately 30 TRPs have been identified and are classified
into TRPA (ankyrin family), TRPC (canonical family), TRPM
(melastatin family), TRPN (NomPC family), TRPML (mucolipin
family), TRPP (polycystin family), and TRPV (vanilloid family)
(Li, 2017). These cationic channels have been shown to be gated
by many physical or chemical stimuli (temperature, membrane
potential, pH, hormones, vitamins . . .). TRP channels are
expressed in various excitable and non-excitable cell types and are
present in many organs, including brain, heart, liver, lung, kidney,
spleen, muscle, skin, pancreas (Venkatachalam and Montell,
2007). Since a decade, TRP channels have attracted much interest
in the cancer field and tumorigenesis. Activities of TRP channels
have been linked to cell growth, survival or migration, being
involved in a plethora of cancers, especially for TRPC, TRPM,
and TRPV (Prevarskaya et al., 2007; Gkika and Prevarskaya, 2009;
Fiorio Pla and Gkika, 2013). Recent research unravels the role of
some TRP channels in glioma growth and progression or glioma
stem-like cell fate determination. In this review, we will mainly
focus on a new class of molecular players, TRP channels emerging
in gliomas and for which we will develop three aspects: (i) the
expression profile and use as clinical markers; (ii) the molecular
mechanisms through which they act; and (iii) their potential use
in therapeutics.
TRANSIENT RECEPTOR POTENTIAL
(TRP) EXPRESSION PROFILE AND
PUTATIVE BIOMARKERS
Changes in expression of TRP channels have been related
to cancer development and progression, thus making them
valuable diagnostic and/or prognostic markers in several tumor
types, including glioma. Furthermore, a strong correlation
between clinical-pathological findings and mRNA and/or protein
expression of different TRPs has been recently provided. For
instance, mRNA encoding TRPC1, TRPC6, TRPM7, TRPM8,
TRPV4, and TRPML2 appeared up-regulated in GBM tumor
specimens in comparison with normal tissues and their
expression was found to increase with glioma tumor grade
with the highest mRNA level found in GBM patient samples
(Ding et al., 2010; Alptekin et al., 2015). These findings are
consistent with a pro-tumorigenic role of these channels in
glioma progression and aggressiveness, as described in more
detail in the next paragraph. According to a qPCR screening
of 33 GBM patient tumors, additional mRNA-encoding TRP
channels including TRPM2, TRPM3, TRPV1, TRPV2 showed
significantly higher expression levels in GBM compared with
control normal brain tissues (Alptekin et al., 2015). However,
other studies reported opposite results, more consistent with an
Frontiers in Cell and Developmental Biology | www.frontiersin.org 2 April 2021 | Volume 9 | Article 617801
fcell-09-617801 April 7, 2021 Time: 12:48 # 3
Chinigò et al. Glioma TRP Channels
anti-tumorigenic function of these channels, as confirmed by
several experimental data (Amantini et al., 2007; Nabissi et al.,
2010; Ying et al., 2013; Morelli et al., 2019). These discrepancies
could be due to the relatively low number of patients considered
in the first study (Alptekin et al., 2015), which may not be very
representative enough while further investigations should now
be reconsidered in light of the new molecular GBM patient
stratification and the methylome.
Among more than 20 TRP channels investigated, TRPM8
showed the highest mRNA upregulation in GBM as compared
with normal brain tissue (Alptekin et al., 2015; Zeng et al.,
2019), suggesting a pivotal function of TRPM8 in gliomagenesis.
Moreover, TRPM8 expression in human GBM specimens and
established GBM cell lines was found to be up-regulated at
both mRNA and protein level to a variable extent (Klumpp
et al., 2017) and to be significantly correlated with worse
patient overall survival (Zeng et al., 2019). Interestingly, it
was previously reported that TRPM8 is a primary androgen-
responsive gene since its promoter is located downstream an
androgen response elements (AREs) to which androgen receptor
(AR) may bind once activated by androgens thus promoting
TRPM8 expression (Bidaux et al., 2005; Asuthkar et al., 2015).
Therefore, TRPM8 overexpression in high-grade glioma might
be associated with the documented upregulation of AR in GBM
(Yu et al., 2015). Moreover, it has been recently found that AR
may also directly regulate TRPM8 channel activity via protein-
protein interaction and/or TRPM8 phosphorylation, further
accentuating the close TRPM8-androgens relationship (Grolez
et al., 2019a; Gkika et al., 2020). Similarly to TRPM8, TRPV4
has been shown to positively correlate with glioma progression,
since high levels of TRPV4 gene and protein expression were
associated with a poorer patient prognosis (Ou-yang et al.,
2018). Thus, TRPM8 and TRPV4 may be currently considered
promising biomarkers accompanying aggressiveness of glioma
and signature of GBM while constituting potential therapeutic
targets for future treatment options. TRPML2 expression was
also detected in normal astrocytes and neural stem/progenitor
cells and to be up-regulated at both mRNA and protein level
in glioma to a variable extent, increasing with the pathological
grade (Morelli et al., 2016). Such observation was linked to the
up-regulation of the transcriptional activator of the TRPML-
2 gene Paired box 5 (PAX5) (Valadez and Cuajungco, 2015)
found in human astrocytoma and correlated with malignancy and
pathological grade of glioma (Stuart et al., 1995).
Moreover, the loss of TRPM3, TRPV1, TRPV2, and TRPML1
expression has been proposed as a negative prognostic marker
for GBM patients, because of their significant and progressive
down-regulation as the tumor grade increases. For instance, a
study focusing on the role of miR-204 in high-grade glioma
cell lines has revealed a significant down-regulation of TRPM3,
due to the hypermethylation of its promoter (Ying et al., 2013).
Interestingly, miR-204 is an intronic miRNA located between
exons 7 and 8 of the TRPM3 gene and its loss in glioma, due to
the high methylation of its host gene TRPM3, is associated with
an enhancement in cell migration and cellular stemness (Ying
et al., 2013) questioning the direct role of TRPM3 and the indirect
regulatory functions of miR-204 via its target genes. Consistently,
restoration of miR-204 in LN382T and SNB19 cells orthotopically
xenografted in the brains of nude mice suppressed tumorigenesis
and invasiveness and increased animal survival (Ying et al., 2013).
Taken together, these findings might suggest a potential tumor-
suppressive function of TRPM3 in glioma, but further studies
are required to clarify its involvement in cancer development
and/or progression and to establish whether TRPM3 and miR-
204 might cooperate with each other in the pathogenesis of
gliomas. Concerning TRPV1 and TRPV2, the preventing role
in gliomagenesis and tumor progression has been more clearly
established and characterized (see next paragraph). First, TRPV1
and TRPV2 genes and protein expression appeared inversely
correlated with glioma grade, showing an almost undetectable
level in GBM (Amantini et al., 2007; Nabissi et al., 2010; Morelli
et al., 2016). In particular, a study performed by Nabissi and
coworkers has shown that GBM and glioma stem-like cells (GSC)
selectively express the TRPV1 5′-untranslated region (5′UTR)
variant three (TRPV1v3), one of the four variants resulting
from alternative first exon splicing (Nabissi et al., 2016). The
5′UTR can generate different transcripts encoding the same
protein but characterized by different stability and translation
efficacy (Audic and Hartley, 2004; Gebauer and Hentze, 2004;
Hinnebusch et al., 2016) and TRPV1v3 is the most stable TRPV1
5′UTR transcript. In GBM, the mRNA expression of the unique
TRPV1v3 variant correlates with the patient’s survival, suggesting
that its loss or low mRNA expression may represent a potential
marker of poor prognosis in GBM patients (Nabissi et al., 2016).
Similarly, the clinical relevance of the overexpression of TRPV2
in GBM was confirmed through the analysis of the TRPV2-
interactome based signature using a systematic proteomics and
computational analysis approach (Doñate-Macián et al., 2018),
predicting GBM patient overall survival. Indeed, high TRPV2
interactome protein expression was correlated with tumor
progression, recurrence, TMZ-resistance and a poor prognosis
(Doñate-Macián et al., 2018). Finally, also TRPML1 might have
a potential role as a negative prognostic marker for GBM patients
(Morelli et al., 2019) since TRPML1 mRNA down-regulation or
loss strongly correlates with reduced overall survival in GBM
patients. However, additional studies are needed in order to
further investigate the relationship between TRPML1 expression
and lower glioma grades (Morelli et al., 2019). However,
TRPML1 expression at mRNA and protein levels displayed
variability within patient samples and its subcellular localization
may also be distinct since TRPML1 is mainly expressed in
the late endosome/lysosome of normal cells while found in
endolysosomes and as dot spots in the nuclear cell compartment
in glioma cells (Morelli et al., 2019). The mechanisms underlying
this nuclear localization in tumor cells and the effects of this
specific localization are not completely characterized, although it
has been shown that TRPML1 is able to bind DNA somehow and
thus, it might affect the transcription of some genes involved in
tumor progression (Morelli et al., 2019).
Together, these studies highlight that some TRPM, TRPV,
and/or TRPML channels overexpressed in glioma should be
considered as predictive and specific biomarkers of high-grade
glioma and GBM, and through changes in their permeability to
cations they may play a role in GBM aggressiveness.
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MOLECULAR MECHANISMS OF TRP
CHANNELS ACTION
Transient receptor potential channels have revealed a direct
involvement in determining many hallmarks of glioma and
GBM (Table 1), including some typical histological cellular
abnormalities (Bomben and Sontheimer, 2008), its relentless
growth, and its intrinsic severe aggressiveness due to its high
capability to diffuse into the non-neoplastic brain parenchyma,
which contributes to treatments resistance and bad prognosis
(Demuth and Berens, 2004; Schwartzbaum et al., 2006; Liu et al.,
2018). TRP channels may exert both anti-tumorigenic and pro-
tumorigenic functions in gliomas and the main TRPs-mediated
signaling pathways associated with gliomas progression are
schematically summarized in Figure 1. Most of the TRP channels
involved in gliomagenesis and tumor progression were found to
affect more than one cellular process related to carcinogenesis. In
this chapter, we will therefore discuss the molecular mechanisms
by which each TRP affects cancer cell behavior, subgrouping them
into subfamilies.
Canonical TRPs
It has been suggested that TRPC channels-relayed mechanisms
may contribute to some of the most common histopathological
hallmarks of GBM such as nuclear atypia and enlarged cell
shape (Bomben and Sontheimer, 2008). Glioma cell lines and
surgical patient-derived tumors have revealed the expression of
four TRP channels belonging to the TRP canonical subfamily that
are TRPC1, TRPC3, TRPC5, and TRPC6. Further investigations
on their role in glioma cells have suggested an involvement
of these channels in a Ca2+ influx pathway impacting cellular
growth. More specifically, it has been shown that TRPC channels
contribute to the resting conductance of glioma cells while
their acute pharmacological inhibition with SKF96365 increased
membrane resistance of glioma cells and caused a transient
hyperpolarization followed by a sustain depolarization of the
cells’ membrane (Bomben and Sontheimer, 2008). Additionally,
chronic application of the TRPC inhibitor SKF96365 (from 0
to 5 days) would lead to an almost complete growth arrest
at the G2/M phase of GBM D54MG cell cycle, as revealed by
FACS analysis (Bomben and Sontheimer, 2008). In most cases
the blockage of the cell cycle during the G2/M transition leads
to cell death (Stark and Taylor, 2006), or in the particular
case of D54MG cells, TRPC inhibition was accompanied by
a continued growth exhibiting multinuclear and enlarged cells
due to incomplete cytokinesis. This phenotype might render
impossible a dynamic adaptation of the cell volume to invade the
brain parenchyma, through the narrow extracellular brain spaces
compatible with less recurrence.
Glioma cells display a depolarized resting membrane potential
around –30 mV. Some TRPC channels are opened at rest
and contribute to this membrane potentials (Bomben and
Sontheimer, 2008). Activation of TRPC channels can also lead
to membrane potentials fluctuations by various ways. First of
all, TRPC channels are non-selective cation channels and they
directly depolarize cells following activation. In addition, TRP
channels are functionally coupled with other ion channels,
so their activation can indirectly lead to depolarizations or
hyperpolarizations, depending on the channels involved (Gees
et al., 2010). In particular, major conductances of glioma cells
are mediated by Ca2+-activated K+ channels (Ransom et al.,
2001) and Cl− channels such as ClC3 or ClC2 (Mcferrin
and Sontheimer, 2006), which both are modulated by TRPC
channels. Glioma cells do express many types of channels
and transporters (Cuddapah and Sontheimer, 2011; Molenaar,
2011), which are sensitive to membrane potential fluctuations.
Furthermore, glioma cells have been shown to display electrical
activities similar to Na+ spikes, which are sustained by TTX-
sensitive voltage-gated Na+ channels (Bordey and Sontheimer,
1998). Thus, TRPC channels may impact many voltage-
dependent cellular processes and modulate electrical behavior
of glioma cells.
Among the TRPCs, TRPC1, and TRPC6 are those for
which the mechanism of action has been best characterized
in human malignant glioma. For instance, TRPC1 was found
to act on several hallmarks of cancer, including growth, cell
cycle and migration. Interestingly, all the TRPC1 effects on
glioma cell behavior strictly resulted from lipid regulation,
e.g., in some cases the channel activity is directly affected
by lipids [phosphatidylinositol-(4,5)-bisphosphate PIP2,
phosphoinositides, diacylglycerol, cholesterol, etc.] localized on
the plasma membrane, in other cases, it can be by signaling
pathways which lead to the production of specific lipids such
as sphingolipids. It has been shown that the loss of TRPC1-
mediated Ca2+ influx upon pharmacological inhibition or
constitutive/inducible shRNA silencing, is associated with
reduced cell proliferation and incomplete cell division, thus
resulting in multinucleated cells similar to those found in patient
biopsies (Bomben and Sontheimer, 2010). The important role
of TRPC1 in glioma cell division has been also confirmed
in vivo through a shRNA knockdown approach on a flank GBM
cell tumor model: TRPC1 downregulation led to a significant
decrease in tumor size, most likely impairing calcium signaling
during cytokinesis (late M-phase) (Bomben and Sontheimer,
2010). TRPC1 has also revealed a role in controlling glioma
cell migration. In particular, it has been shown that TRPC1 is
essential for chemotactic migration in human malignant gliomas
in response to chemoattractant growth factors like epidermal
growth factor (EGF) and platelet-derived growth factor (PDGF)
which affect TRPC1 activity through different signaling pathways
(Bomben et al., 2011; Lepannetier et al., 2016). Stimulation with
EGF was associated with a re-localization of TRPC1 channel
at the leading edge of migrating D54MG glioma cells within
lipid rafts, specialized membrane microdomains enriched in
cholesterol and sphingolipids (Mollinedo and Gajate, 2015). In
agreement, it has been shown that both TRPC1 channel activity
and lipid raft integrity were required for gliomas chemotaxis
(Bomben et al., 2011). Moreover, the disruption of lipid rafts
by depletion of cholesterol not only affected chemotaxis but
also impaired TRPC currents in whole-cell recordings and
decreased store-operated Ca2+ entry (SOCE), confirming a
direct interplay between lipid rafts and TRPC1 channels and
localized Ca2+ rise in regulating the chemotactic movement of






















Biological effect Mechanism Potential therapeutic
tools
References
TRPC1 Yes ↑ Cell growth (+) ↑ Cytokinesis TRPC1/SPK/PI3K
inhibitors
Bomben and Sontheimer, 2008; Bomben and
Sontheimer, 2010
Cell migration (+) ↑Chemotaxis Bomben et al., 2011; Lepannetier et al., 2016
TRPC6 Low ↑ Cell growth (+) → NFAT TRPC6/NFAT inhibitors Chigurupati et al., 2010; Ding et al., 2010
Cell migration (+) → RhoA Chigurupati et al., 2010
Angiogenesis (+) → NFAT
Radioresistance (+) ↑ G2/M (Cdc25C) Ding et al., 2010
TRPM2 Yes ↑ Cell death (+) ↑ ROS-induced Ca2+ influx TRPM2 gene insertion
(+ Se and DXT)
Ishii et al., 2007; Ertilav et al., 2019
TRPM3 Yes ↑/↓ n.d. n.d. n.d. Ying et al., 2013; Alptekin et al., 2015
TRPM7 Yes ↑ Cell growth (+) ↑ STAT3/Notch TRPM7/STAT3/Notch/
ALDH1 inhibitors
miR-28-5p
Liu et al., 2014; Wan et al., 2019
amiR-28-5p a Rap1b
Cell invasion (+) amiR-28-5p a Rap1b Wan et al., 2019
Stem cell renewal and
differentiation (+)
STAT3-ALDH1 ↑ Liu et al., 2014
TRPM8 Yes ↑ Cell migration (+) ↑ BK channels RTK signaling Wondergem et al., 2008; Wondergem and
Bartley, 2009; Klumpp et al., 2017
(2 different
isoforms)
Cell growth (+) → BK channels→ CaMKII acdc25C a cdc2 MAPK
signaling
Klumpp et al., 2017; Zeng et al., 2019
Cell death (–) MAPK signaling Klumpp et al., 2017; Zeng et al., 2019
Radioresistance (+) Supporting DNA repair and cell cycle upon genotoxic
stress
Klumpp et al., 2017
TRPV1 Yes ↓ Apoptosis (+) → p38 MAPK Amantini et al., 2007
↑ ER stress (ATF3) Stock et al., 2012
TRPV2 Yes ↓ Cell proliferation (–) ERK signaling Nabissi et al., 2010; Morelli et al., 2012
Apoptosis (+) Fas signaling Nabissi et al., 2010
Cell differentiation (+) ↑ GFAP and βIII-tubulin expression ↑ Aml-1 a
(PI3K/AKT pathway)
CBD Morelli et al., 2012; Nabissi et al., 2015
Drug sensitivity (+) ↑ drug uptake ↑ drug-mediated apoptotic pathway CBD + TMZ/BCNU/
DOXO
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glioma cells (Bomben et al., 2011). It must be noted that TRPC
pharmacological inhibition through non-selective inhibitors
caused an almost complete loss of chemotactic migration but
TRPC1 knockdown through shRNA compromised directional
migration but did not eliminate it and did not affect non-
directional motility. This suggests TRPC1 specific implication
in chemotactic migration and the potential implication of other
TRPC channels in migration processes (Bomben et al., 2011).
As shown by a more recent study by Lepannetier et al. (2016),
lipids are not only important for the regulation of TRPC1
at the membrane level, but also through their signaling. The
authors shed light on another store-independent mechanism by
which TRPC1 may be activated and thus affect cell migration
in GBM. In particular, they have shown that PDGF may induce
the translocation of TRPC1 from the cytosolic compartment to
the front of migrating cells through a mechanism requiring the
phosphoinositide-3 kinase (PI3K) and at the same time induces
the production of the lipid second messenger sphingosine-1-P
(S1P) which in turn, activates TRPC1-mediated Ca2+ entry.
Indeed, the PDGF-induced Ca2+ influx through TRPC1 can be
partially inhibited by pretreatment of the cells with a specific
inhibitor of the sphingosine kinase (SPK) producing S1P
(Lepannetier et al., 2016). However, whether S1P directly or
indirectly triggers TRPC1-mediated and store-independent
entry of Ca2+ channel remains to be clarified (Lepannetier et al.,
2016). In any case, it has been well established that both TRPC1
targeting to the leading edge of lamellipodia and its activation
by S1P are essential in regulating PDGF-induced chemotaxis in
U251 glioblastoma cells (Lepannetier et al., 2016).
Another member of the TRPC subfamily specifically
implicated in glioma progression is TRPC6. Indeed, TRPC6 was
found to affect different hallmarks of GBM including tumor
growth, cell survival, invasiveness and angiogenesis (Chigurupati
et al., 2010; Ding et al., 2010). More specifically, it has been
demonstrated that under hypoxia, which is one of the main
characteristics of GBM aggressiveness, invasion and resistance to
treatment (Flynn et al., 2008), Notch1 activation consequently
led to TRPC6 upregulation in primary GBM samples and cell
lines (Chigurupati et al., 2010). Indeed, the inhibition/silencing
of TRPC6 was associated with a reduction in glioma growth,
invasion and angiogenesis. This Notch1-mediated induction
of TRPC6 expression in hypoxic U373 cell line was subtype-
specific, since other members of the TRPC subfamily were
unaffected, indicating that TRPC6 is primarily responsible for
the hypoxia-induced sustained increase in the intracellular Ca2+
concentration. Additionally, it has been proven that TRPC6 is
essential for GBM cell survival, since its downregulation not
only suppressed cell growth in vitro and reduced tumor volume
in vivo, but also impaired clonogenic ability, induced cell cycle
arrest at the G2/M phase, and enhanced the antiproliferative
effect of ionizing radiation.
An accelerated G2 phase progression may lead to an impaired
DNA damage checkpoint and thus to an enhanced genomic
instability, explaining the TRPC6 association with enhanced
glioma cell malignancy. Mechanistically, TRPC6 effects on
cell proliferation, tumor growth and angiogenesis seemed to
be directly mediated by the Ca2+-induced activation of the
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FIGURE 1 | TRPs-mediated signaling pathways in gliomas. (A) Anti-tumorigenic TRPs-mediated signaling pathways in gliomas. Cartoon depicting TRP channels
signaling pathways suppressing gliomas progression through the inhibition of pro-tumorigenic pathways (in red) and/or the activation of anti-tumorigenic signaling
pathways (in green). TRPM2 and TRPML1 upon ROS activation promote cell apoptosis through an increase in oxidative stress and intracellular Ca2+ concentration;
due to its localization on the lysosomal membrane TRPML1 may also mediates the autophagic cell death pathway through the interaction with HSP; TRPA1 under
hypoxia promotes apoptosis inducing ROS formation and inhibiting antioxidants such as GSH; TRPV1 upon stimulation with CPS triggers the apoptotic pathway
through p38 MAPK and reduces glioma expansion via ER pathway in a ATF3-dependent manner; TRPV2 reduces cell proliferation and enhances the Fas-induced
(Continued)
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FIGURE 1 | Continued
apoptosis in an ERK-dependent manner; TRPV2 also acts on cell differentiation since its overexpression is associated with GFAP and βIII-tubulin increased
expression and its activation by CBD promotes Aml-1 up-regulation via PI3K/AKT pathway; finally, TRPV2 activation by CBD can improve cell sensitivity to
chemotherapeutic agents favoring drug uptake. (B) Pro-tumorigenic TRPs-mediated signaling pathways in gliomas. Cartoon depicting TRP channels signaling
pathways promoting gliomas progression through the activation of pro-tumorigenic pathways (in red) and/or the inhibition of anti-tumorigenic signaling pathways (in
green). TRPC1 affects cell growth and cell proliferation mainly promoting cytokinesis in response to lipid activation, whereas upon stimulation with growth factors it
induces chemotactic migration; TRPC6 affects cell proliferation, tumor growth and angiogenesis likely through the Ca2+-induced activation of the calcineurin-NFAT
pathway, whereas TRPC6 effects on cell migration might rather involve Rho activation and subsequent actin cytoskeleton rearrangements; TRPV4 promotes cell
migration and tumor invasiveness through the AKT-mediated Rac1 activation; TRPM8 supports glioma progression by inhibiting apoptosis through MAPK pathway
and impairing the cell cycle through the activation of BK channels and the subsequent CaMKII-mediated inhibition of phosphatases like Cdc25C and Cdc2; TRPM8
effects on cell migration/invasion are also associated with BK channels activation and the function of TRPM8 in aggressiveness and resistance to treatment may also
be potentiated by TKR-mediated HGF/SF stimulation; TRPM7 increases glioma cell proliferation and invasion through the down-regulation of miR-28-5p and the
subsequent up-regulation of oncogenic signaling pathways involving AKT, ERK, IGF-1 and Rap1b; TRPM7 effects on glioma proliferation may also be mediated by
Notch and/or JAK2/STAT3 signaling pathways and through the activation of STAT3; TRPM7 might also be involved in GSC renewal and differentiation thanks to the
up-regulation of the well-known GSC marker ALDH1; the hypermethylation of TRPM3 promoter through the down-regulation of miR-204 enhances cell migration;
TRPML2 enhances cell proliferation and slows down apoptosis improving DNA repair and inhibiting Caspase 3 likely through PI3K/AKT and ERK1/2 pathways.
Abbreviations: ROS, reactive oxygen species; HSP, heat shock proteins; GSH, glutathione; CPS, capsaicin; ATF3, transcription factor-3; CBD, cannabidiol; GFAP,
glial fibrillary acidic protein; Aml-1, acute myeloid leukemia transcription factors; PI3K, phosphoinositide 3-kinases; AKT, protein-kinase B; HGF/SF, hepatocyte
growth factor/scatter factor; EGF, epidermal growth factor; PDGF, platelet-derived growth factor; TKR, tyrosine kinase receptor; NFAT, nuclear factor of activated
T-cells; MAPK, mitogen-activated protein kinase; BK, big potassium channels; CaMKII, Ca2+/calmodulin-dependent protein kinase II; Cdc25C and Cdc2, cell
division cycle proteins; JAK2, janus kinase 2; STAT3, signal transducer and activator of transcription 3; ERK, extracellular signal-regulated kinases; IGF-1, insulin-like
growth factor-1; GSC, glioma stem cells; ALDH1, aldehyde dehydrogenase 1.
calcineurin-NFAT pathway (Chigurupati et al., 2010), whereas
TRPC6 effects on cell migration might rather involve Rho
activation and subsequent actin cytoskeleton rearrangements
(Singh et al., 2007). Together, these data stress a possible role
of TRPC6 as a promising therapeutic target in the treatment of
human GBM (Chigurupati et al., 2010; Ding et al., 2010).
Melastatin TRPs
Four TRP melastatin subfamily members, TRPM2, TRPM3,
TRPM7, and TRPM8, have been implicated in glioma cell growth,
proliferation and migration. Among them, TRPM2 and TRPM3
would exert anti-tumorigenic effects, while TRPM7 and TRPM8
may contribute to glioma malignancy.
TRPM2 is known for its role as a sensor of oxidative stress
and inductor of necrotic cell death upon activation by reactive
oxygen species (ROS) (Naziroğlu and Lückhoff, 2008; Takahashi
et al., 2011). TRPM2 expression likely induced no effect on cell
proliferation, migration and invasion. But in A172 human GBM
cells the transfection with TRPM2 channels increased cell death
induced by H2O2 in a Ca2+-dependent manner (Ishii et al., 2007)
and in human GBM (DBTRG) cells, TRPM2 activation led to an
increase in oxidative stress and intracellular Ca2+ concentration,
thus promoting GBM cell death through apoptosis (Ertilav et al.,
2019). Concerning TRPM3, which is the most recently described
melastatin subfamily member, Its roles and action mechanisms
were only recently investigated (Zamudio-Bulcock et al., 2011).
Like TRPM2, TRPM3 may show a protective role in glioma
probably via the miR-204 regulation (Ying et al., 2013), but its
function needs further studies.
TRPM7 also controls glioma progression through miRNA
regulation in GBM cells with subsequent effects on cell
proliferation and invasion (Wan et al., 2019). More specifically,
TRPM7 expression can be associated with a decreased production
of miR-28-5p, a tumor suppressor inhibiting the expression
of oncogenic signaling pathways involving protein-kinase B
(AKT) (Xiao et al., 2018), ERK (Liu et al., 2016), and
IGF-1 (Shi and Teng, 2015). Accordingly, the downregulation
of miR-28-5p caused a significant increase in glioma cell
proliferation and invasion. Among miR-28-5p targets, expression
of Rap1b appeared as being positively correlated with TRPM7
in GBM and was up-regulated in tumor samples due to the
suppression of the repressing role of miR-28-5p (Wan et al.,
2019). This miR-28-5p/Rap1b axis shown in gliomagenesis
is not the exclusive signaling route in which TRPM7 acts
on GBM progression. Indeed, TRPM7 may also regulate the
Notch pathway (Liu et al., 2014), recently shown as linked
with Rap1b signaling and integrin-mediated cell adhesion in
hematopoietic stem cells (Rho et al., 2019). This can be connected
with the role of TRPM7 on cell proliferation, migration and
invasion in glioma cells and GSCs through the upregulation
of JAK2/STAT3 and/or Notch signaling pathways (Liu et al.,
2014). Moreover, TRPM7 was found to activate STAT3, which in
turn binds to the aldehyde dehydrogenase1 (ALDH1) promoter
upregulating the expression of this well-known GSC marker
involved in many pathways maintaining stem cell-like state
(Rasper et al., 2010), when expanded as spheroids (Liu et al.,
2014). Since ALDH1 is functionally involved in self-protection,
differentiation, expansion and proliferation (Choudhary et al.,
2005; Ma and Allan, 2011), this potentially means that
TRPM7 is not only implicated in proliferation, migration
and invasion, but also in GSC renewal and differentiation.
This has to be put into the context that TRPM7 channel
exhibits an intrinsic kinase activity, thus supporting that
TRPM7 effects on glioma cell growth are mediated by its
channel activity while cell migration and invasion required its
kinase domain (Wan et al., 2019). The discovery of different
cellular and molecular targets affecting gliomas development and
progression through their modulation by TRPM7 provides key
insights for the development of novel therapeutic agents for
glioma treatments.
TRPM8 was found to affect the rate of GBM cell migration
by mediating a significant increase in intracellular Ca2+
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concentration upon stimulation with specific agonists such
as menthol and icilin (Wondergem et al., 2008; Wondergem
and Bartley, 2009; Klumpp et al., 2017). It has been shown
that TRPM8 activation by icilin leads to a significant increase
in the migration speed and chemotaxis of GBM cells and,
consistently, TRPM8 downregulation by RNA interference
as well as TRPM8 inhibition by the specific channel blocker
BCTC [N-(4-tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tet
rahydropyrazine-1(2H)-carbox-amide] reduces cell migration
rate and decreases transfilter chemotaxis (Klumpp et al., 2017).
One of the possible mechanisms through which TRPM8-
mediated Ca2+ influx may affect cell migration in glioma is
by the activation of the large-conductance Ca2+-activated K+
ion channels (BK channels) (Wondergem and Bartley, 2009).
BK channels contribute to maintaining the plasma membrane
ionic fluxes essential to support cell shrinkage-driven cell
migration (Mcferrin and Sontheimer, 2006). Interestingly, BK
overexpression was detected in human glioma cells (Ransom
and Sontheimer, 2001) and pharmacological inhibition of
BK channels was shown to abolish the menthol-stimulated
Ca2+ influx within the cell cytoplasm and cell migration
suggesting a key role of TRPM8. TRPM8 activation by agonists
has been shown to increase the open probability of single
BK channels (Wondergem and Bartley, 2009; Klumpp et al.,
2017). In agreement, ionizing radiation, known to induce
the migration through a Ca2+-mediated activation of BK
channels (Steinle et al., 2011; Edalat et al., 2016), has been
shown to activate and upregulate TRPM8-mediated Ca2+
influx in glioma cells (Klumpp et al., 2017), thus confirming
a direct and reciprocal interplay between these two channel
families in the control of GBM migration. The function of
TRPM8 in aggressiveness and resistance to treatment was
suggested by the potentiating impact of hepatocyte growth
factor/scatter factor (HGF/SF), a multifunctional effector of
cells expressing the Met tyrosine kinase receptor (TKR), on
TRPM8-induced Ca2+ homeostasis and cell migration. This
evidence suggests that TRPM8 might converge to a common
HGF/SF and cMET, known to play a role in malignancy of
solid tumors including glioma (Laterra et al., 1997; Birchmeier
et al., 2003; Wondergem et al., 2008), signaling pathway leading
to migration/invasion. An enhancement in the invasion rate
of human GBM cells has also been associated with TRPM8
overexpression (Zeng et al., 2019). However, DBTRG cells
would express two different variants of TRPM8 (Wondergem
et al., 2008) as revealed in Western blot showing a molecular
band at 130–140 kDa in the plasma membrane-enriched
fraction and consistent with the molecular weight of TRPM8
full-length isoform (Peier et al., 2002), and a second molecular
band at 95–100 kDa in microsome- and membrane-enriched
fractions more consistent with a truncated TRPM8 splice
variant expressed in the endoplasmic reticulum (ER) (Bidaux
et al., 2007). The observed greater increase in menthol-
induced Ca2+ influx among migrating cells compared with
non-migrating cells (Wondergem et al., 2008), likely indicates
that only migrating cells express full-length TRPM8 protein
within the plasma membrane. However, these results have
to be taken with caution in a future context of drug therapy,
since TRPM8 was shown to have an anti-migratory activity
in other cancers including prostate cancer and may play
a role in the tumoral and tumor-derived endothelial cells
(Gkika et al., 2010, 2015; Genova et al., 2017; Grolez et al.,
2019b). TRPM8 contribution to GBM progression was found
to go far beyond its effects on cell migration and invasion,
significantly affecting other determinant processes such as
cell cycle, cell survival and radioresistance (Klumpp et al.,
2017; Zeng et al., 2019). Indeed, it has been proven that
TRPM8 inhibition or knockdown impaired the cell cycle,
triggered apoptotic cell death and attenuated DNA repair
and clonogenic survival (Klumpp et al., 2017). A recent study
by Zeng et al. (2019) have suggested an involvement of the
mitogen-activated protein kinase (MAPK) signaling pathway
in TRPM8-mediated effects on cell proliferation and apoptosis,
since the expression of the channel was associated with the
expression levels of important regulators of these pathways,
including extracellular signal-regulated kinase (ERK), cyclin D1
and the apoptosis-related protein Bcl-2 in human glioma cells.
Moreover, it has been shown that TRPM8 signaling directly
regulates the cell cycle, contributing to S phase progression
and mitosis. These effects on glioma’s cell cycle are most likely
mediated by intracellular signaling pathways involving the
Ca2+/calmodulin-dependent protein kinase II (CaMKII) and
some Cdc phosphatases like Cdc25C and Cdc2, which control
entry into, and progression through, various phases of the cell
cycle (Klumpp et al., 2017). More specifically, the TRPM8-
mediated Ca2+ entry, through the activation of BK channels,
may increase the CaMKII activity, which in turn inhibits the
Cdc2 subunit of the mitosis-promoting factor likely through
the inhibitory phosphorylation of the Cdc25C phosphatase
(Klumpp et al., 2017). Finally, TRPM8 channel might also
modulate proliferation by dynamically control glioma resting
potentials levels, which are key regulator of cell cycle. TRPM8
agonists have been shown to increase the Kir4.1 mediated
membrane conductances of glioma cells (Ratto et al., 2020).
Kir4.1 is an inward rectifier K+ channel, with an altered pattern
of expression in glioma. In astrocytes, it is responsible for
high potassium conductance and hyperpolarized membrane
potential (Olsen and Sontheimer, 2008). Overexpression of this
channel in glioma cell lines D54MG reduces cell proliferation
(Higashimori and Sontheimer, 2007). Thus, TRPM8 channel
by regulating K+ resting conductances of glioma cells may
exert a regulation of cell cycle transitions. Moreover, TRPM8
has also been found to be a contributor to the genotoxic stress
response of GBM upon treatment with ionizing radiation,
restoring G1/S transition and S phase progression to levels
of unirradiated cells (Klumpp et al., 2017). Interestingly, it
has been found that ionizing radiation stimulated TRPM8
availability both in vitro and in vivo and that TRPM8 played a
role in the re-entry in mitosis and cell division upon radiation-
induced G2/M arrest, since its knockdown resulted in an
impaired DNA repair and a decreased survival of irradiated cells
(Klumpp et al., 2017). This, combined with the slowdown of
apoptosis in irradiated GBM cells, may explain the enhanced
radioresistance acquired by GBM cells overexpressing TRPM8,
thus stressing that the key interest of targeting TRPM8 alone
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or in combination with radiotherapy for future treatments
of GBM.
Vanilloid TRPs
Some TRP members of the vanilloid family have been related
to gliomagenesis and progression. More specifically, TRPV1
and TRPV2 have revealed a protective role in glioma cells by
regulating cell proliferation and survival, stem cell differentiation
and sensitivity to drugs, whereas TRPV4 was found to increase
cancer cell invasiveness.
The anti-tumorigenic functional role of TRPV1 in gliomas,
suggested by its marked downregulation or loss in patients
with the shortest overall survival, has been investigated and
several findings highlighted a role of TRPV1 in the induction
of apoptotic cell death signaling in gliomas (Amantini et al.,
2007; Stock et al., 2012). Upon exposure to low doses of the
TRPV1 specific agonist capsaicin (CPS), the TRPV1-Ca2+ may
sustain apoptosis in gliomas through the selective activation
of p38 MAPK, but not ERK MAPK (Amantini et al., 2007).
More in detail, it has been shown that CPS-mediated TRPV1
activation leads to reduced cell viability, DNA fragmentation,
externalization of phosphatidylserine on the outer layer of
the plasma membrane, mitochondrial transmembrane potential
dissipation, and caspase 3 activation (Amantini et al., 2007).
Moreover, TRPV1 translation in GBM was found to be sensitive
to interferon-gamma (INF-γ) and to the well-known autophagic
inducer rapamycin (Rap), suggesting a link between TRPV1
channel and autophagy often related to pro-survival in tumors
including GBM (Galluzzi et al., 2015) but also in migration (Coly
et al., 2017). This biological effect might be achieved by the
TRPV1-mediated induction of apoptosis previously reported in
GBM cells (Amantini et al., 2007).
One of the mechanisms through which the brain, especially
in the juvenile phase, can protect itself against high-grade
astrocytoma (HGAs) involves the activation of TRPV1 by
neural precursor cells (NPCs), known to show extensive tropism
for brain tumors (Mayor et al., 2001). Interestingly, NPCs
accumulate at HGA especially in the context of the juvenile
brain, exhibiting a high proliferative activity in the stem cell
niche (Walzlein et al., 2008), and can release tumor-suppressive
factors, such as endovanilloids able to activate TRPV1 expressed
by HGA cells (Stock et al., 2012). The activation of the latter
would trigger astrocytoma cell death through the ER pathway in a
transcription factor-3 (ATF3)-dependent manner, thus reducing
glioma expansion mostly in young brain (Stock et al., 2012).
In light of these data, the inverse correlation between TRPV1
expression and glioma grade from I to III and the reduced or
lost TRPV1 expression found in GBM patients is most likely a
mechanism by which tumor cells may evade anti-proliferative
and pro-apoptotic signals. This hypothesis is also supported by
the finding that TRPV1 is also downregulated in GSCs (Stock
et al., 2012), whose resistance to cytotoxic therapies and to pro-
apoptotic signals is accepted (Bao et al., 2006a). Furthermore, the
induction of GSCs differentiation was accompanied by TRPV1v3
expression at a similar level than found in low-grade glioma, thus
confirming a protective role of this channel against aggressiveness
(Nabissi et al., 2016).
TRPV2 exerts its anti-tumorigenic function on gliomas
through the regulation of several signaling pathways involved
in cell proliferation and survival, stem cell differentiation
and sensitivity to drugs. Physiologically, the triggering of
TRPV2 by agonists/activators such as growth factors, hormones
and cannabinoids led to TRPV2 translocation from the
endosome to the plasma membrane, where it mediates several
pathways associated with cell proliferation and cell death
(Liberati et al., 2014). Thus, loss or alterations of TRPV2
expression in cancer cells results in an impairment of these
processes, as shown in prostate tumor-derived endothelial
cells (Bernardini et al., 2019) and gliomas (Liberati et al.,
2014). In gliomas, it has been shown that TRPV2 reduced
cell proliferation and increased cell sensitivity to Fas-induced
apoptosis in an ERK-dependent manner (Nabissi et al.,
2010). Consistently, enhanced cell growth and rescuing from
apoptotic cell death was observed when TRPV2 was silencing
in U87MG GBM cells. In contrast, TRPV2 upregulation in
MZC primary glioma cells, by inducing Fas overexpression
led to reduced viability and increased spontaneous as well as
Fas-induced apoptosis (Nabissi et al., 2010). Similar findings
were also described in GSCs, whose proliferation appeared
strongly impaired by TRPV2 pharmacological inhibition or
knocking down (Morelli et al., 2012). In GSCs, TRPV2
acts also on differentiation (Morelli et al., 2012; Nabissi
et al., 2015). More specifically, TRPV2 overexpression was
associated with glial fibrillary acidic protein (GFAP) and βIII-
tubulin increased expression, thus promoting a glial phenotype
differentiation while inhibiting GSCs proliferation both in vitro
and in vivo. In agreement, TRPV2 silencing or inhibition
during differentiation impaired differentiation and reduced
GFAP and βIII-tubulin expression (Morelli et al., 2012).
Moreover, TRPV2 activation through cannabidiol (CBD) was
found to trigger GSCs differentiation activating the autophagic
process, in addition to inhibiting GSCs proliferation and
clonogenic capability (Nabissi et al., 2015). More specifically,
it has been observed that CBD, through the TRPV2-mediated
activation of the PI3K/AKT pathway, upregulated the expression
of acute myeloid leukemia (Aml-1) transcription factors,
known for their pivotal role in GBM proliferation and
differentiation. Furthermore, it has also been shown that the
spliced variant Aml-1 a, upregulated during GSCs differentiation,
directly influenced the expression of TRPV2 by binding its
gene promoter (Nabissi et al., 2015), thus establishing a
positive feedback circuit, which on the whole caused glial
differentiation.
Conversely to TRPV1 and TRPV2, TRPV4 has revealed
a pivotal role in promoting glioma progression (Ou-yang
et al., 2018). In particular, the tumorigenic potential of TRPV4
comes from its critical involvement in glioma cell migration
and invasion. Indeed, it has been demonstrated that TRPV4-
mediated Ca2+ influx upon stimulation with the selective agonist
GSK1016790 A, is able to promote cell migration of glioma
cells (Ou-yang et al., 2018), a similar mechanism previously
reported in breast cancer (Lee et al., 2017). It was established that
TRPV4 effects on cell migration are relayed by phosphorylation
of AKT (P-AKT) and activation of Rac1 (Ou-yang et al., 2018), a
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member of the Rho GTPases family known for its central role in
cytoskeleton remodeling, cell motility and cell adhesion as well as
for its involvement in the enhanced migration of several tumor
types including GBM, colon, colorectal and ovarian cancer (Guo
et al., 2015; Guéguinou et al., 2016; Qin et al., 2017; Zhou et al.,
2018). Accordingly, TRPV4 blockade, induced by the specific
TRPV4 inhibitor HC-067047, was found to decrease motility and
invasiveness of U87 glioma cells through a P-AKT and Rac1
signaling pathway (Ou-yang et al., 2018).
Mucolipin TRPs
The two TRP members of mucolipin subfamily have revealed
opposite effects on glioma carcinogenesis.
TRPML1 showed a protective role against glioma progression.
Indeed, it has been shown that TRPML1 activation by its
specific agonist MK6-83 reduced T98 and U251 cell line viability
and increased caspase 3-dependent apoptosis. Accordingly,
TRPML1 silencing or pharmacological inhibition restored
cell viability suppressing the Ca2+ influx responsible for
apoptosis induction. Furthermore, TRPML1 may also mediate
the autophagic cell death pathway, upon cell treatment with
the ROS inducer carbonyl cyanide m-chlorophenylhydrazone
(CCCP) (Morelli et al., 2019). Indeed, high ROS levels may trigger
a TRPML1-mediated lysosomal Ca2+ release and the subsequent
enhancement of autophagy (Zhang et al., 2016b). Accordingly,
TRPML1 silencing or inhibition by sphingomyelin pre-treatment
reverted CCCP effects (Morelli et al., 2019). In this context,
it has also been demonstrated that TRPML1, through a large
intraluminal loop between its first and second transmembrane
domains, may interact with chaperone-mediated autophagy-
related proteins such as the heat shock proteins Hsc70, and
Hsp40 (Venugopal et al., 2009). Therefore, TRPML1 may exert
its cytotoxic effects through two different pathways, e.g., (i) it can
act as a ROS sensor on the lysosomal membrane and attenuate
oxidative cell stress through an autophagy-dependent negative-
feedback mechanism (Zhang et al., 2016a; Morelli et al., 2019)
or (ii) it may trigger Ca2+ release but no ROS production
upon direct activation by its specific agonist, thus inducing
apoptosis (Morelli et al., 2019). Moreover, the important role
of TRPML1 in controlling intracellular Ca2+ homeostasis has
been further corroborated by the recent finding of a functional
localization of TRPML1 at the so-called “mitochondria-lysosome
contact sites” where it mediates a calcium flux from lysosomes to
mitochondria adjuvanted by VDAC and MCU on the outer and
inner mitochondrial membranes, respectively (Peng et al., 2020).
Consequently, TRPML1 functions go beyond the regulation of
lysosomal dynamics and function and, through the control of
mitochondrial Ca2+ dynamics, can affect other Ca2+-dependent
mitochondrial functions, including oxidative phosphorylation,
motility, and ROS signaling (Peng et al., 2020).
Conversely to TRPML1, the other member of the mucolipin
family, TRPML2, has revealed a pro-tumorigenic function in
glioma progression. Indeed, it has been shown that TRPML2
enhanced glioma cell survival and proliferation (Morelli et al.,
2016). More in detail, TRPML2 suppression leads to impaired
cell cycle, reduced cell viability and decreased proliferation
(Morelli et al., 2016). In addition, its knocking-down was found
to induce apoptosis by increasing DNA damage, Ser139 H2AX
phosphorylation and caspase-3 activation (Morelli et al., 2016).
TRPML2 effects on tumor progression are probably mediated by
PI3K/AKT and ERK1/2 pathways, since these pathways remained
inactivated in TRPML2-silenced cells (Morelli et al., 2016). Thus,
TRPML2 might also be an interesting therapeutic target to
control GBM cell survival and proliferation.
THERAPEUTIC TARGETING
Considering the altered expression and the great contribution
given by TRP channels to the establishment and progression of
glioma, they may be considered very promising new therapeutic
molecular targets against which novel drug compounds must be
developed. One of the main advantages provided by most TRPs
is their accessibility from the extracellular side, which makes
them efficient targetable sites via administration of specific TRPs
inhibitors or blockers when these channels are overexpressed in
high-grade glioma. For instance, some of the TRPC channels by
interfering with cytokinesis pathways would be promising targets
for the development of drugs able to interfere with the almost
unrestrained growth of gliomas, making tumors more susceptible
to surgical removal or focal radiotherapy. Moreover, the low
specificity of some TRPC modulators might allow to achieve
a higher antitumor effect, through the simultaneous triggering
of more than one channel. The progressive understanding
of the molecular mechanism underlying TRPC function in
glioma has also provided opportunities and arguments in
favor of small molecule targeted therapies. Through studies
concerning TRPC1 and its specific pharmacological inhibition,
the key option by inhibiting SPK or PI3K inhibitors is once
again here confirmed to attempt controlling GBM growth
and invasiveness. Among TRPC channels, great potential as
a promising new candidate for GBM treatment comes from
TRPC6. Among TRP, TRPC6 is to date the only one being
implicated in GBM angiogenesis suggesting that specific TRPC6
inhibitors could simultaneously target both cancer progression
and vascularization, thereby improving the efficacy of standard
(radio-chemotherapy) options. The barely detectable TRPC6
expression in normal glial cells should limit the potential side
effects on normal glial cells. But a possible impact of TRPC6
blockade on neurons must be considered in regards to the central
role of TRPC6 in neuronal functions (Tai et al., 2008; Zhou
et al., 2008; Kim et al., 2017). A possible strategy to overcome
this problem might be the use of viral vectors as a drug delivery
system toward glioma cells since adenovirus may target glioma
cells more efficiently than neurons (Ding et al., 2010).
As recurrence is due to migration and invasion (and
resistance to treatment), pharmacological inhibition of TRPV4
might represent a potential new therapeutic approach in GBM
treatment to control migratory and invasive capabilities of GBM
cells (Ou-yang et al., 2018). One of the mechanisms through
which tumor cells are able to sustain a prolonged survival is
by the inhibition of apoptotic pathways (Thompson, 1995).
In this context, TRPA1 has been recently proposed as a new
potential therapeutic target in GBM treatment. Indeed, TRPA1 is
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a ROS-sensitive cation channel and can subsequently be activated
by hypoxia-induced oxidative stress (Naziroğlu, 2012; Takahashi
et al., 2018). It has been shown that TRPA1 activation following
cobalt chloride (CoCl2) treatment with the aim to mimic hypoxia,
may increase apoptosis, inflammation and oxidative effects on
DBTRG cells (Deveci et al., 2019). More specifically, TRPA1-
mediated Ca2+ entry was associated with an enhancement of
ROS production and mitochondrial membrane depolarization
(JC-1). Moreover, TRPA1 activation leads to increased levels of
Annexin V, cytokines IL-1β and IL-18, and caspase 3 and 9
and decreased levels of thiol cycle antioxidants (GSH and GSH-
Px) (Deveci et al., 2019). These effects were shown attenuated
by α-lipoic acid (ALA) treatment, a physiological source of
energy for cells which may exert both anti- and pro-oxidant
functions (Moini et al., 2002). In glioma cells under hypoxia,
ALA likely acts as an antioxidant agent, upregulating GSH and
GSH-Px and down-regulating mitochondrial ROS production,
thus blocking TRPA1-mediated induction of apoptotic cell
death (Deveci et al., 2019). This suggests that targeting and
activating TRPA1 or targeting TRPV1 in glioma exhibiting such
expression, can restore apoptotic signaling and might provide
new insights for the development of alternative therapies against
glioma progression.
Besides being potential anti-tumor targets, TRP channels
should play a role as “drug carriers” in cancer therapy, facilitating
via the central pore chemotherapy drug uptake thus improving
the efficacy of cancer therapies. For instance, TRPV2 activation
by CBD can sensitize GBM cells to chemotherapeutic agents
currently used, e.g., TMZ, carmustine (BCNU) and doxorubicin
(DOXO) (Nabissi et al., 2013, 2015). The CBD-induced TRPV2
activation was found to increase GSCs sensitivity to cytotoxic
effects of alkylating agents like BCNU favoring drug uptake
(Nabissi et al., 2013), in synergy with the Ca2+-dependent
triggering of apoptotic cell death, a mechanism not found in
normal astrocytes (Nabissi et al., 2015). Specifically, by using
the natural red fluorescent DOXO, it has been demonstrated
that TRPV2 overexpression in MZC glioma cells markedly
increased DOXO uptake in a Ca2+-dependent manner, since
Ca2+ chelation by EGTA completely inhibited the CBD-
induced TRPV2-mediated increase of DOXO-positive cells
(Nabissi et al., 2013). Similar findings were also observed in
hepatocellular carcinoma in which TRPV2 activation by CBD
or 2-APB (Aminoethoxydiphenyl borate) was found to improve
DOXO permeation into tumor cells, thus corroborating an
intriguing role of TRPV2 in increasing tumor cell sensitivity
to chemotherapy drugs (Neumann-Raizel et al., 2019). Taking
into account other evidence on the role of TRP channels
as “drug carriers” thanks to the permeation of chemotherapy
agents into the cell through their pore domain (Santoni and
Farfariello, 2011), it is reasonable to speculate that the activation
of TRPV2 channel may cause a conformational change in the
pore helix structure, which allow for intracellular non-specific
chemotherapy uptake (Nabissi et al., 2013), opening the route
for combinatorial co-administration of TRPV2 specific agonist
CBD and lower chemotherapeutic doses to overcome the high
resistance of GBM and GSCs to chemotherapeutic agents. In
this context, recent developments on the role of the so-called
“pore turret,” i.e., the region of the extracellular ring that connects
the S5 helix to the pore helix, in controlling the upper gate
of some TRP channels including TRPV2 (Dosey et al., 2019)
have provided new insights into the role of TRPV2 as a drug
target to reduce GBM chemoresistance. Indeed, the well-defined
pore turret, in addition to allowing the coupling between the
lower gate and the upper gate in response to intracellular stimuli
stabilizing a fully open unliganded channel, represents a possible
and interesting binding site for extracellular modulators through
which it may affect channel activity allowing the passage through
the plasma membrane of partially hydrophilic molecules which
otherwise could not enter the cell (Dosey et al., 2019).
With a view to looking ahead, some data indicate that
TRP channels may constitute targets of gene therapy. It has
been recently shown that TRPM2 can promote cell death
(Ertilav et al., 2019). Therefore, TRPM2 might represent a
good candidate for gene therapy to be used for instance in
combination with γ-radiation and/or chemotherapeutic agents
to improve the effectiveness of GBM treatments. Preliminary
observations indicate that Selenium (Se) tested on GBM cells
resistant to Docetaxel (DTX) may improve the apoptotic efficacy
of DTX through the activation of TRPM2 by oxidative stress
(Ertilav et al., 2019). The cytotoxic effect of DTX likely comes
from the formation of excessive mitochondrial ROS and Ca2+
influx into the cells which causes DNA damage by triggering
hyperactivation of the DNA nick sensor PARP, thus leading to
NAD+ and ATP depletion and subsequent apoptotic cell death
(Ertilav et al., 2019). In this case, Se, in particular, stimulated
oxidative stress production in the mitochondria, which in turn
activated a TRPM2-mediated Ca2+ influx, thus supporting and
enhancing the same Ca2+-dependent apoptotic pathway induced
by DTX and other chemotherapeutic agents, as seen also in
other tumor types (Hazane-Puch et al., 2016; Çetin et al., 2017).
Overall the combination and synergistic activity of Se and DTX
in GBM expressing TRPM2 might offer a new option for adjuvant
chemotherapy as treatment of GBM.
FUTURE PERSPECTIVES
Increasing understanding of the signaling pathways involved in
tumorigenesis has made it possible to identify a wide range
of molecular targets involved in self-renewal and proliferation,
angiogenesis but also in invasion of GBM cells. A number
of therapeutic strategies have therefore been developed during
the last decade and few of them have proven to be effective,
even though anti-angiogenic treatments appear to be able to
provide a 6 months delay for GBM patients before recurrence.
It is, therefore, necessary to identify other therapeutic targets
that can be combined with anti-angiogenic, cytotoxic, DNA
repair inhibitors and/or immunotherapy strategies. In this
context, targeting the activity of factors or components expressed
by glioma cells themselves and by other cell types of the
micro-environment would also be promising. It has also
to be considered that main RNAseq and/or transcriptomic
databases were constituted by means of the glioma tumor
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bulk composed of the different populations of GBM cells
and other constituents such as endothelial cells, pericytes,
reactive astrocytes, macrophages (M1 and/or M2), microglial,
neurons, and potentially lymphocytes, depending on the level
of heterogeneity GBM subgroup. New potential family targets,
expressed at the plasma membrane and involved in survival,
GSC differentiation, angiogenesis and invasion, constitute a
choice option. TRP channels not systematically ubiquitously
expressed, potentially playing pleiotropic mechanisms and being
overexpressed in pathologic situations such as hypoxia in glioma
cells deserve to be more explored, especially since they could
be also expressed by other cell types belonging to the tumor
micro-environment.
For instance, a direct involvement of TRP channels in vascular
endothelial growth factor (VEGF) signaling pathways affecting
brain neovascularization and tumor growth it has been proven.
GCSs positive for CD133 (human prominin-1/AC 133) not
only are capable of self-renewal and proliferation, but also
possess the capability to secrete high levels of VEGF (Bao
et al., 2006b; Yao et al., 2008), known to play a crucial role
in endothelial cell recruitment and angiogenesis of malignant
human gliomas (Fischer et al., 2005; Bian et al., 2006). In
GSCs isolated from U87 cell line the production of VEGF
and the angiogenic CXCL8 (chemokine interleukin-8) by tumor
cells appeared to be mediated by a G protein-coupled receptor
named formylpeptide receptor (FPR) which, upon activation,
induces directional migration, growth and angiogenic factors
production through a Ca2+ mobilization. Although a direct
involvement of TRPs in this Ca2+-mediated mechanism has
not been highlighted, a GCPR-TRP axis in many signaling
pathways is nowadays well established (Veldhuis et al., 2015).
Moreover, an interesting crosstalk between TRPM8, TRPV1 and
the VEFG receptor (VEGFR) it has been recently characterized
in uveal melanoma, suggesting a good potential for TRPM8 as
a pharmacological target for blocking brain neovascularization
and tumor growth (Walcher et al., 2018). Indeed, it has been
demonstrated that in different cell types including corneal
epithelial and endothelial cells (Lucius et al., 2016) and uveal
melanoma cells (Walcher et al., 2018) the activation of TRPM8
inhibits the VEGF transactivation of TRPV1 and the consequent
pro-tumorigenic effects mediated by the VEGFR. These findings
further highlighted the central role played by TRPs interactions
with other TRP channels, other channels families like that of
BK channels, and the GCPRs, in affecting signaling pathways
directly involved in carcinogenesis and brain tumor progression.
Moreover, they strongly sustain the possible TRPs application in
anti-angiogenic therapy.
However, to date, to the best of our knowledge TRPC6 is
the only TRP channel directly implicated in GBM angiogenesis.
TRPC6 has been found to play a key role in promoting
GBM growth, angiogenesis and invasion under hypoxia through
Notch1 (Chigurupati et al., 2010). TRPC6 knockdown or NFAT
inhibition has been shown to reduce the number of branch
points and thus impair the ability of the hypoxic U373MG to
induce endothelial cell tube formation in vitro, suggesting a
role of TRPC6 in the “vascular mimicry” played by glioma cells
(Chigurupati et al., 2010).
Other TRPs among those previously described to have a
function in gliomas, such as TRPM2, TRPM7, TRPV2, and
TRPV4 have also been found in brain vasculature, thus suggesting
a possible double function for these channels in affecting glioma
progression (Hatano et al., 2013; Pires and Earley, 2017; Ou-
yang et al., 2018; Luo et al., 2019) and contributing to GBM
angiogenesis. Regarding TRPA1 and TRPC3 not likely described
in glioma, some studies highlighted their involvement in other
brain vasculature diseases, exerting a protective role against
ischemic damage, controlling vasodilation in brain endothelial
cells (Sullivan et al., 2016; Pires and Earley, 2018). TRPC3, when
overexpressed, would lead to an increase in the BBB permeability,
leading to vasogenic edema formation (Ryu et al., 2013).
CONCLUSION
Taken together all these data suggest a key role of some TRP
channels in high-grade glioma development and angiogenesis.
The current activators or inhibitors directed against these
channels should provide lead compounds and knowledge for
future research in the design of drugs targeting simultaneously
glioma cells and key components of the micro-environment such
as abnormal tumoral vascularization.
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